Biologics in Inflammatory Immune-mediated Systemic Diseases

被引：20
|
作者：
Moroncini, Gianluca [1 ]
Calogera, Giovanni [1 ]
Benfaremo, Devis [1 ]
Gabrielli, Armando [1 ]
机构：
[1] Univ Politecn Marche, Dipartimento Sci Clin & Mol, Clin Med, Via Tronto 10-A, I-60126 Ancona, Italy
来源：
CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 2017年 / 18卷 / 12期
关键词：
ANCA-associated vasculitis; Behcet Disease; belimumab; rituximab; Systemic Lupus Erythematosus (SLE); Systemic Sclerosis (SSc); TNF-inhibitors; tocilizumab; RANDOMIZED CONTROLLED-TRIAL; ONSET STILLS-DISEASE; GIANT-CELL ARTERITIS; LOW-DOSE RITUXIMAB; ANTI-TNF AGENTS; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; BEHCETS-DISEASE; LUPUS-ERYTHEMATOSUS; MONOCLONAL-ANTIBODY;
D O I：
10.2174/1389201019666171226152448
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Background: The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases. Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.
引用
收藏
页码：1008 / 1016
页数：9
相关论文
共 50 条
  • [41] Urine metabolome profiling of immune-mediated inflammatory diseases
    Arnald Alonso
    Antonio Julià
    Maria Vinaixa
    Eugeni Domènech
    Antonio Fernández-Nebro
    Juan D. Cañete
    Carlos Ferrándiz
    Jesús Tornero
    Javier P. Gisbert
    Pilar Nos
    Ana Gutiérrez Casbas
    Lluís Puig
    Isidoro González-Álvaro
    José A. Pinto-Tasende
    Ricardo Blanco
    Miguel A. Rodríguez
    Antoni Beltran
    Xavier Correig
    Sara Marsal
    BMC Medicine, 14
  • [42] Management of cardiovascular comorbidities in immune-mediated inflammatory diseases
    Roubille, C.
    REVUE DE MEDECINE INTERNE, 2024, 45 (04): : 194 - 199
  • [43] Pneumococcal vaccine in adults with immune-mediated inflammatory diseases
    Kapetanovic, Meliha C.
    LANCET RHEUMATOLOGY, 2024, 6 (09): : e591 - e592
  • [44] OAS family and immune-mediated inflammatory skin diseases
    Zheng, Y.
    Chen, X.
    Xu, F.
    Man, X.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S161 - S161
  • [45] Management of cardiovascular comorbidities in immune-mediated inflammatory diseases
    Roubille, C.
    REVUE DE MEDECINE INTERNE, 2022, 43 : A299 - A303
  • [46] IMMUNE-MEDIATED INFLAMMATORY DISEASES: A NEW MULTIDISCIPLINARY CONCEPT
    Baeten, Dominique
    van Hagen, Martin
    Magro, Fernando
    Filipe, Paulo
    Fonseca, Joao Eurico
    ACTA REUMATOLOGICA PORTUGUESA, 2009, 34 (03): : 457 - 459
  • [47] Breast inflammatory gigantomastia in a context of immune-mediated diseases
    Touraine, P
    Youssef, N
    Alyanakian, MA
    Lechat, X
    Balleyguier, C
    Duflos, C
    Dib, A
    May, A
    Carel, JC
    Laborde, K
    Sigal-Zafrani, B
    Goffin, V
    Eymard, B
    Boitard, C
    Brousse, N
    Kuttenn, F
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (09): : 5287 - 5294
  • [48] Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases
    Larsen, Rasmus
    Gouveia, Zelia
    Soares, Miguel P.
    Gozzelino, Raffaella
    FRONTIERS IN PHARMACOLOGY, 2012, 3
  • [49] Cancer risk in immune-mediated inflammatory diseases (IMID)
    Rudi Beyaert
    Laurent Beaugerie
    Gert Van Assche
    Lieve Brochez
    Jean-Christophe Renauld
    Manuelle Viguier
    Veronique Cocquyt
    Guy Jerusalem
    Jean-Pascal Machiels
    Hans Prenen
    Pierre Masson
    Edouard Louis
    Filip De Keyser
    Molecular Cancer, 12
  • [50] Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases
    van Lint, Jette A.
    Jessurun, Naomi T.
    Hebing, Renske C. F.
    Hoentjen, Frank
    Tas, Sander W.
    Vonkeman, Harald E.
    van Doom, Martijn B. A.
    Sobels, Annemieke
    Spuls, Phyllis, I
    van Puijenbroek, Eugene P.
    Nurmohamed, Michael T.
    van den Bemt, Bart J. F.
    DRUG SAFETY, 2020, 43 (09) : 917 - 925
12345